TCG Crossover Management LLC Sells 329,344 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

TCG Crossover Management LLC trimmed its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 37.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 550,000 shares of the company's stock after selling 329,344 shares during the period. TCG Crossover Management LLC owned about 1.36% of Keros Therapeutics worth $8,706,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of KROS. JPMorgan Chase & Co. lifted its position in Keros Therapeutics by 585.9% in the 4th quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company's stock valued at $3,379,000 after acquiring an additional 182,314 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Keros Therapeutics in the fourth quarter valued at about $388,000. Barclays PLC boosted its position in shares of Keros Therapeutics by 140.1% during the third quarter. Barclays PLC now owns 60,014 shares of the company's stock worth $3,484,000 after buying an additional 35,022 shares during the period. Norges Bank bought a new position in shares of Keros Therapeutics during the fourth quarter worth about $1,027,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Keros Therapeutics in the 4th quarter valued at approximately $461,000. 71.56% of the stock is currently owned by institutional investors.

Insider Activity

In related news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of Keros Therapeutics stock in a transaction that occurred on Wednesday, April 9th. The shares were acquired at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the transaction, the insider now directly owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. This represents a 27.01 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 22.90% of the stock is currently owned by company insiders.

Keros Therapeutics Price Performance

KROS stock traded up $0.08 during midday trading on Friday, reaching $14.65. 651,753 shares of the company were exchanged, compared to its average volume of 811,465. The firm has a market capitalization of $594.95 million, a price-to-earnings ratio of -2.81 and a beta of 1.32. The business has a 50-day moving average price of $11.92 and a two-hundred day moving average price of $26.07. Keros Therapeutics, Inc. has a one year low of $9.12 and a one year high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $3.04 million during the quarter, compared to analysts' expectations of $37.32 million. As a group, analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on KROS shares. Oppenheimer reduced their price target on Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a research report on Thursday, January 16th. Cantor Fitzgerald cut shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday, January 21st. Scotiabank lowered their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a research note on Thursday, January 16th. Truist Financial reduced their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. Finally, Piper Sandler reduced their price target on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research report on Friday, January 17th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $40.33.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.